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Quality-adjusted life-years (QALYs) were the summary benefit measure. They were discounted at an annual rate of 3.5%.
Cost data:
The direct costs included were treatment of recurrences and distant recurrences, terminal care, cancer treatment, outpatient care, genomic testing with Oncotype DX test, and chemotherapy-related toxicities treatment (including gut perforation, bleeding, thrombosis, allergic reactions and hypertension). Resource use was taken from published studies and National Institute for Health and Clinical Excellence (NICE) guidelines. Unit costs were from the UK NHS reference costs. Drug costs were from the British National Formulary. All costs were reported in UK £. The price year was 2011. Future costs were discounted at an annual rate of 3.5%.
Analysis of uncertainty:
A probabilistic analysis was conducted by varying all the uncertain model parameter inputs simultaneously in a Monte Carlo simulation (with 10,000 simulations). A one-way sensitivity analysis was also conducted. A value-of-information analysis was undertaken to provide a framework for setting priorities for further research.
Results
For patients who received Oncotype DX-directed chemotherapy, the QALYs gained were 10.32 and the cost per patient was £23,130.
For patients who received standard care (chemotherapy alone), the QALYs gained were 10.16 and the cost per patient was £22,270.
Costs and benefits were combined using an incremental cost-utility ratio (the additional cost per QALY gained). When compared with standard care, the incremental cost-utility ratio of Oncotype DX-directed chemotherapy was £5,529 per QALY gained.
Results of the probabilistic sensitivity analysis showed that a £30,000 per QALY threshold, the probability that Oncotype DX-directed chemotherapy was cost-effective was 0.61; at a £20,000 per QALY threshold, the probability that it was cost effective was 0.58.
Results of the value-of-information analysis showed that the overall maximum expected healthcare resource lost as a consequence of uncertainty in cost-effectiveness was in excess of £2,000 million.
Authors' conclusions
The authors concluded that although genomic test-directed chemotherapy was cost-effective, there was substantial uncertainty surrounding the results and that further research collecting long-term outcome data was needed.
CRD commentary

Interventions:
The interventions were clearly reported. The comparator (standard chemotherapy) was relevant to the study setting.
Effectiveness/benefits:
Clinical and effectiveness data were derived from a number of different sources including national statistics, published studies and trials, and expert opinion. The authors did not report how published studies were identified or if a systematic review of the literature was undertaken. As a result, it was not possible to determine if all the relevant information was included. However, the main estimates of effectiveness were derived from clinical trials published recently in high-impact peer reviewed journals. Most of the effectiveness data were from randomised controlled trials, so it was likely that these estimates were internally valid. QALYs were an appropriate benefit measure, which captured the impact of the interventions on quality of life and survival. The details of the derivation of the utility values would have been useful to fully assess their validity.
Costs:
For the explicitly stated UK NHS perspective, all relevant cost categories and costs appear to have been included. The sources for unit costs and resource use were adequately reported; they appeared to be appropriate to the study setting.
